Earnings summaries and quarterly performance for CODEXIS.
Executive leadership at CODEXIS.
Board of directors at CODEXIS.
CR
Christos Richards
Detailed
Director
CC
Cynthia Collins
Detailed
Director
DS
David Smith
Detailed
Lead Independent Director
DW
Dennis Wolf
Detailed
Director
EM
Esther Martinborough
Detailed
Director
RS
Rahul Singhvi
Detailed
Director
RD
Raymond De Vré
Detailed
Director
SD
Stephen Dilly
Detailed
Chair of the Board
SP
Stewart Parker
Detailed
Director
Research analysts who have asked questions during CODEXIS earnings calls.
MH
Matthew Hewitt
Craig-Hallum Capital Group LLC
4 questions for CDXS
Also covers: ACET, APYX, BHST +21 more
Allison Bratzel
Piper Sandler Companies
3 questions for CDXS
Also covers: ABCL, AKBA, ALXO +5 more
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
3 questions for CDXS
Also covers: ABCL, ABSI, ARWR +19 more
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
3 questions for CDXS
Also covers: A, AVTR, DHR +15 more
Kristen Kluska
Cantor Fitzgerald
3 questions for CDXS
Also covers: ABEO, ADMA, AQST +24 more
JJ
Jacob Johnson
Stephens Inc.
2 questions for CDXS
Also covers: AZTA, CDMO, CERS +11 more
MS
Matthew Stanton
Jefferies
2 questions for CDXS
Also covers: AZTA, BLFS, CYRX +5 more
CW
Chad Wiatrowski
TD Cowen
1 question for CDXS
Also covers: BLFS, CTKB, MASS +4 more
Jack Melick
Jefferies
1 question for CDXS
Also covers: HOLX, QDEL
RM
Rick Miller
C.L. King & Associates
1 question for CDXS
Also covers: ABEO, ADMA, FULC
Tycho Peterson
Jefferies
1 question for CDXS
Also covers: A, AVTR, BIO +22 more
Recent press releases and 8-K filings for CDXS.
Codexis Reports Q3 2025 Results and Announces Strategic Transformation and CEO Change
CDXS
Earnings
CEO Change
Guidance Update
- Codexis reported total revenues of $8.6 million for Q3 2025, compared to $12.8 million in Q3 2024, and a net loss of $19.6 million, or $0.22 per share, for Q3 2025.
- The company is undergoing a strategic transformation to become a full-service manufacturing innovator in oligonucleotide manufacturing, shifting its focus from the historical small molecule biocatalysis business to the Eco-synthesis and ligase business lines.
- Alison Moore, current Chief Technical Officer, will succeed Stephen Dilly as CEO, with Dilly transitioning to Executive Chair.
- A supply assurance agreement with Merck was signed, providing a vital non-dilutive cash infusion, with a significant portion of revenue to be recognized in Q4 2025 and the remainder in Q1 2026, leading the company to expect to meet or slightly exceed the top end of its 2025 revenue guidance.
- Restructuring efforts, including headcount reductions, are projected to reduce the company's burn by approximately 25% and extend the cash runway through 2027.
Nov 6, 2025, 9:30 PM
CDXS Announces Q3 2025 Results, Executive Leadership Transition, and Cost Reduction Initiatives
CDXS
Earnings
Management Change
Layoffs
- For Q3 2025, CDXS reported total revenue of $8.6 million, a decrease from $12.8 million in Q3 2024, and a net loss per share of ($0.22). The product gross margin improved to 64% from 61% in the prior year period.
- The company secured a $37.8 million Supply Assurance Agreement with Merck, with cash expected by the end of 2025, which is anticipated to provide a cash runway through 2027. A significant portion of this revenue is expected to be recognized in Q4 2025.
- Dr. Alison Moore will assume the role of President and CEO, with Dr. Stephen Dilly transitioning to Chairman. Georgia Erbez, CFO, will also take on the additional title of Chief Business Officer.
- CDXS is eliminating 46 positions, a measure expected to reduce operating expenses by 25%.
Nov 6, 2025, 9:30 PM
Codexis Reports Q3 2025 Financial Results, Announces CEO Change, and Strategic Initiatives
CDXS
Earnings
CEO Change
Layoffs
- Codexis reported total revenues of $8.6 million for the third quarter of 2025, a decrease from $12.8 million in Q3 2024, and a net loss of $19.6 million, or $0.22 per share.
- The company signed a $37.8 million Supply Assurance Agreement with Merck in October 2025, with the cash anticipated by year-end.
- Codexis announced a workforce reduction of approximately 24% (46 positions) in November 2025, expecting an additional expense of $3.5 million in Q4 2025, as part of efforts to extend its cash runway through 2027.
- Alison Moore will succeed Stephen Dilly as President and Chief Executive Officer effective November 7, 2025, with Dilly transitioning to Chairman of the Board.
Nov 6, 2025, 9:29 PM
Codexis Announces Q2 2025 Financial Results and Business Update
CDXS
Earnings
Debt Issuance
New Projects/Investments
- Codexis reported Q2 2025 revenue of $15.3 million, exceeding the analyst consensus estimate of $14.1 million.
- The company strengthened its cash position by raising $27.3 million through an at-the-market (ATM) facility and an Innovatus loan. As of June 30, 2025, Codexis had $66.3 million in cash, cash equivalents, and short-term investments.
- The ECO Synthesis platform gained significant external validation with six presentations at the 2025 TIDES USA annual meeting, including three from CDMO collaborators. The company anticipates achieving pilot scale GLP-grade siRNA production and signing a GMP scale-up partner by the end of 2025.
Aug 13, 2025, 8:05 PM
Codexis Provides Update on Ecosystems Platform and Commercial Strategy
CDXS
New Projects/Investments
Product Launch
Guidance Update
- Codexis's GLP Eco Innovation Lab is operational and has secured its first revenue-generating contract for the Ecosystems Platform, involving manufacturing a novel construct for a pharma innovator with a CDMO partner.
- The company expects four customers to purchase its ligase by the end of 2025, up from one last year, with three CDMOs (Bachem, Nitto, ST Pharma) already seeing the advantage of access to their ligase.
- Codexis recently rolled out a machine learning AI platform for ligase selection, enabling rapid optimization of molecules for specific reactions.
- The company plans to cost-effectively build a 50 kilo annual capacity GMP facility for siRNA production, estimated to cost $30 million over two years for a 35,000 square foot facility.
- Codexis aims to reach cash flow positive by the end of 2026, supported by its profitable heritage pharma manufacturing business.
Aug 4, 2025, 4:41 PM
Quarterly earnings call transcripts for CODEXIS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more